SCHEMBL2889826

SCHEMBL2889826

Nc1nc(N)c(-c2ccc(Cc3ccnc4[nH]cc(Cl)c34)c(F)c2)c(C(F)(F)F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 4/20 0.41
CDK2 P24941 2/20 0.33
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK9 P50750 1/20 0.33
CCNA1 P78396 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
CYP3A4 P08684 4/20 0.32
CDC7 O00311 1/20 0.32
CHEK1 O14757 1/20 0.32
AURKA O14965 1/20 0.32
PDPK1 O15530 1/20 0.32
DAPK3 O43293 1/20 0.32
DYRK3 O43781 1/20 0.32
CACNA1F O60840 1/20 0.32
RAF1 P04049 1/20 0.32
ERBB2 P04626 1/20 0.32
NTRK1 P04629 1/20 0.32
INSR P06213 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2886384 0.82 ROCK2 (0.38) ROCK2CDK2CCNT1CCNA2CDK9
SCHEMBL4770061 0.82 ROCK2 (0.53) ROCK2CDK2CYP3A4CDC7CHEK1
SCHEMBL4765307 0.79 ROCK2 (0.63) ROCK2CDK2CYP3A4CDC7CHEK1
SCHEMBL2887558 0.77 ADRA2B (0.39) ROCK2CDK2CCNT1CCNA2CDK9
SCHEMBL8270533 0.76 ROCK2 (0.66) ROCK2CDK2CYP3A4CDC7CHEK1
SCHEMBL4775724 0.74 ROCK2 (0.57) ROCK2CDK2CCNT1CCNA2CDK9
SCHEMBL2884975 0.73 ROCK2 (0.39) ROCK2CDK2CYP3A4CDC7CHEK1
SCHEMBL4765301 0.73 ROCK2 (0.57) ROCK2CDK2CYP3A4CDC7CHEK1
SCHEMBL4768374 0.70 ROCK2 (0.42) ROCK2CDK2CYP3A4CDC7CHEK1
SCHEMBL4772585 0.70 ROCK2 (0.49) ROCK2CDK2CYP3A4CDC7CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 ROCK2 4593/4885CDK2 457/4885CCNT1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.